Liquid Biopsy Market

Key data points: Market size in 2027 = $7090 million 2035 = $12,387 million, growth forecast = 7.2% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in liquid biopsy market to 2035 by product (assays kits, instruments, and services), circulating biomarker (circulating tumor cells, circulating tumor DNA, cell-free DNA, extracellular vesicles, and others), application (oncology and non-cancer), end use (reference laboratories, hospitals & physician laboratories, academic & research centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Liquid Biopsy Market The future of the global liquid biopsy market looks promising with opportunities in the reference laboratory, hospital & physician laboratory, and academic & research center markets. The global liquid biopsy market is expected to reach an estimated $12,387 million by 2035 from $7090 million in 2027 with a CAGR of 7.2% from 2027 to 2035. The major drivers for this market are the increasing use of precision medicine is driving market expansion, the rising need for non-invasive diagnosis solution, and the growing use of liquid biopsy in treatment monitoring. • Lucintel forecasts that, within the product category, assay kits is expected to witness the highest growth over the forecast period due to improvement in ease of use and standardization of assay kits. • Within the end use category, hospitals & physician laboratories is expected to witness the highest growth over the forecast period due to stronger adoption of liquid biopsy by hospital laboratories. • In terms of regions, APAC will remain the largest region over the forecast period due to growing accessibility of the healthcare system and investments in cancer diagnostics. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Liquid Biopsy Market The liquid biopsy market is experiencing rapid growth driven by technological advancements, increasing cancer prevalence, and a shift towards minimally invasive diagnostic methods. As healthcare providers seek more accurate, faster, and less invasive options for cancer detection and monitoring, the market is evolving with innovative solutions and expanding applications. These developments are not only improving patient outcomes but also transforming clinical workflows and healthcare economics. The following key trends highlight the dynamic nature of this market and its trajectory toward personalized medicine and improved diagnostic precision. • Adoption of Multi-Analyte Testing: This trend involves combining various biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes to enhance diagnostic accuracy. Multi-analyte testing provides comprehensive insights into tumor heterogeneity and resistance mechanisms, enabling more precise treatment decisions. As technology advances, labs can detect multiple biomarkers simultaneously, reducing turnaround times and improving sensitivity. This approach is expected to become standard practice, broadening the scope of liquid biopsy applications across different cancer types and stages. • Integration of Artificial Intelligence (AI) and Machine Learning: AI and machine learning algorithms are increasingly being integrated into liquid biopsy platforms to analyze complex data sets. These technologies improve the interpretation of genetic and molecular information, identify patterns, and predict treatment responses. AI-driven analytics enhance diagnostic accuracy, reduce false positives/negatives, and facilitate personalized treatment planning. As AI tools become more sophisticated, they will enable real-time data analysis, streamline workflows, and support clinicians in making more informed decisions, ultimately improving patient outcomes. • Expansion Into Non-Cancer Applications: While initially focused on oncology, liquid biopsy is now expanding into other medical fields such as infectious diseases, prenatal testing, and autoimmune disorders. For example, detecting viral DNA or RNA in blood samples can aid in diagnosing infections, while fetal DNA analysis offers non-invasive prenatal testing options. This diversification broadens the market scope, increases demand, and encourages innovation in assay development. As research progresses, liquid biopsy could become a versatile tool for various diagnostic needs beyond cancer. • Development of Companion Diagnostics and Personalized Therapies: The rise of targeted therapies has driven the need for companion diagnostics that identify specific genetic mutations. Liquid biopsies are increasingly used to match patients with personalized treatment regimens, monitor therapeutic efficacy, and detect resistance mutations early. This trend supports the shift toward precision medicine, enabling tailored treatments that improve efficacy and reduce side effects. The integration of liquid biopsy into clinical workflows for therapy selection and monitoring is expected to accelerate, fostering closer collaboration between diagnostic and pharmaceutical industries. • Regulatory Approvals and Standardization Efforts: As liquid biopsy technologies mature, regulatory agencies are establishing guidelines for validation, approval, and clinical use. Standardization of sample collection, processing, and analysis methods is critical to ensure reproducibility and reliability across laboratories. Recent approvals of liquid biopsy tests for specific cancers have increased market confidence and adoption. Ongoing efforts to develop international standards and regulatory frameworks will facilitate broader acceptance, reimbursement, and integration into routine clinical practice, ultimately driving market growth and innovation. These emerging trends are reshaping the liquid biopsy market by enhancing diagnostic accuracy, expanding application areas, and integrating advanced technologies. They are fostering a shift toward personalized, minimally invasive, and rapid diagnostics, which will significantly impact patient care, clinical workflows, and the overall healthcare landscape. Recent Developments in the Liquid Biopsy Market The market for liquid biopsies is advancing through growing diagnosis needs, increasing cancer incidence and the emphasis on less invasive diagnostic procedures. Significant investments and research in liquid biopsies have improved diagnosis and encouraged their adoption in the field. There is a vast opportunity for companies to focus on newly developed procedures in liquid biopsies and further expand their applications in the field. • Rising Cancer Diagnoses: The incidence of cancer has increased worldwide and liquid biopsies provide an opportunity for the diagnosis of cancer at early stages and facilitate the monitoring of cancer. Compared to other types of biopsies, liquid biopsies are less invasive. There is increased opportunity for companies to expand and improve the liquid biopsy market. • Improved Detection Methods: Improvements in research and technology have enhanced the precision of liquid biopsies. Detection of genetic mutations has also improved and allows for the diagnosis of cancer at early stages. Liquid biopsies are also useful to monitor minimal residual disease and cancer relapses. Continuous decline in costs of liquid biopsies promotes their use in the field. • Personalized Medicine: Liquid biopsies provide a means to gauge the genetics of a patient’s tumor. This, in turn, gives doctors the opportunity to determine the best course of treatment. It gives them the ability to assess the efficacy of the treatment, and alter the treatment plan if necessary. It is undeniably clear that cancer patients benefit from the use of liquid biopsies. With more emphasis placed on tailored treatment plans, there is an increasing demand for liquid biopsies. • Early Diagnosis and Continuous Disease Management: Liquid biopsies are altering how we diagnose and manage cancer. Not only are these tests improving early cancer detection and diagnosis, but they provide oncologists with a means to assess treatment and plan long-term management. Above all, liquid biopsies provide a means to determine if cancer has returned or progressed. Because of all of this, the market is rapidly growing. New companies are devising new, more effective ways of tailoring treatment to the individual needs of each patient. • Strategic Alliances and Regulatory Changes: More partnerships among biotech and pharma companies, as well as healthcare services companies, has promoted the development and sale of liquid biopsy products. More regulatory approvals have also occurred. While partnerships and approvals often happen in parallel to one another, the former helps explain the latter. For example, a partnership may focus on the development of a diagnostic test. Once the test receives regulatory approval, the partnership has facilitated the development of a diagnostic test and paved the way for the commercialization of the test. Along these lines, the liquid biopsy marketplace has also changed to include competitors, as well as distributors and validation service providers. The combined result of the changes in the marketplace has been an increase in the number of companies developing and commercializing liquid biopsy products. The changes have also increased the number of applications for liquid biopsy products. Additionally, the changes have increased the opportunities for the field, including the potential to improve the diagnostic testing process to reduce costs and improve effectiveness. Strategic Growth Opportunities in the Liquid Biopsy Market The liquid biopsy market is projected to grow at a rapid pace in the coming years. This is mostly due to improvements in technology and the increasing incidence of cancer. The decline in size of invasive procedures, such as biopsies, is another reason that has increased interest in this type of diagnostic testing. There are many ways in which a company can exploit this growing market. The company that focuses on improving diagnostic tests in this field will have a competitive advantage. • Expansion Into Personalized Medicine Through Liquid Biopsy: One important factor that helps explain the potential of this market is the increasing interest in precision or personalized medicine. Liquid biopsies, in some cases, may help healthcare workers monitor genomic changes that may occur during cancer treatment. This helps the healthcare worker customize the treatment, and in some cases may reduce the side effects of cancer treatment. Improving our understanding of the genomic changes that occur during cancer treatment is essential to help promote further investment in this area. • Increasing Adoption in Early Cancer Detection and Screening: Another opportunity is in the area of cancer screening and early detection. For many cancers, if the disease is detected and treated earlier, it may result in improved patient survival. Several ongoing studies are combining liquid biopsies with early detection and cancer screening. It is expected that in the future, there will be improved ways to detect and diagnose many types of cancers using liquid biopsies. • Improvements in Assay Technology: As research and development in the field of assay technology progresses, the specificity and sensitivity of liquid biopsies increases. Detecting rare biomarkers and eliminating false positive results are key factors in improving the clinical usefulness of a biopsy test. As the reliability of liquid biopsies increases, their use in the field of oncology and other areas of medicine will increase as well. Increased confidence on the part of the clinician and the patient is important for the acceptance of new diagnostic tests and technologies in the field of medicine. Newer and more advanced diagnostic technologies are likely to receive regulatory approval in the near future. • Key Alliances and Partnerships: Alliances and partnerships between pharmaceutical, biotech and other related services and businesses help expand a company's customer base and market. Joint alliances help companies accelerate the launch of new products. New company alliances help businesses faster adapt to changing market conditions. Companies are expected to focus on key alliances and joint ventures to integrate liquid biopsy technologies in common clinical practices and accelerate revenues. • Current Trends in Liquid Biopsy: The advancements made in the field of liquid biopsies provide the opportunity to examine tumor behavior and address challenges in therapy. Through the use of circulating tumor DNA (ctDNA) and other tumor-associated biomarkers in body fluids, it is possible to evaluate the effects of current therapy and identify mechanisms of therapy resistance in a timely manner. With this continual assessment of oncologic patients, efforts can be directed to optimize therapy and avoid the administration of unnecessary, potentially harmful therapies. There is great potential to broaden and enhance the assays used in liquid biopsies to better adapt to the challenges in cancer therapeutics. The prospects described above are anticipated to boost the concentration and scope of the market and enhance services provided to patients. Companies that recognize and develop the opportunities described above will enhance their position in the marketplace and contribute to broader services in the field of oncology. The combined efforts of industries and the healthcare service sector can improve the services offered to patients and further transform the field of oncology. Liquid Biopsy Market Drivers and Challenges The liquid biopsy market is influenced by a range of technological, economic, and regulatory factors that shape its growth trajectory. Advances in molecular diagnostics and personalized medicine are driving innovation, while increasing healthcare expenditure and demand for minimally invasive procedures are expanding market opportunities. Regulatory approvals and reimbursement policies also play a crucial role in market development. However, challenges such as high costs, lack of standardization, and regulatory hurdles pose significant barriers. Understanding these drivers and challenges is essential for stakeholders to navigate the evolving landscape and capitalize on emerging opportunities in this dynamic sector. The factors responsible for driving the liquid biopsy market include:- • Technological Advancements: The rapid development of sensitive detection techniques like next-generation sequencing (NGS) and digital PCR has significantly improved the accuracy and reliability of liquid biopsies. These innovations enable early detection of cancer and real-time monitoring of treatment response, fostering confidence among clinicians and patients. As technology continues to evolve, costs are decreasing, making liquid biopsies more accessible. This progress supports the shift toward personalized medicine, where tailored treatments improve patient outcomes and reduce healthcare costs, thereby fueling market growth. • Rising Incidence of Cancer: The increasing prevalence of cancer worldwide, driven by aging populations, lifestyle factors, and environmental exposures, is a major market driver. Early detection and monitoring are critical for effective treatment, and liquid biopsies offer a minimally invasive alternative to traditional tissue biopsies. The ability to detect circulating tumor DNA (ctDNA) and other biomarkers in blood samples facilitates early diagnosis, prognosis, and treatment customization. As cancer cases continue to rise, demand for liquid biopsy solutions is expected to grow substantially, expanding market opportunities across regions. • Growing Adoption of Personalized Medicine: The shift toward personalized treatment strategies is a key factor propelling the liquid biopsy market. By providing molecular insights into tumor genetics, liquid biopsies enable clinicians to select targeted therapies and monitor their effectiveness. This approach reduces unnecessary treatments and associated side effects, improving patient quality of life. The increasing acceptance of precision medicine in oncology and other therapeutic areas encourages healthcare providers and payers to adopt liquid biopsy techniques, thereby expanding their use and driving market expansion. • Favorable Regulatory Environment and Reimbursement Policies: Regulatory approvals from agencies such as the FDA and EMA have validated the clinical utility of liquid biopsy tests, boosting market confidence. Additionally, reimbursement policies are gradually evolving to cover these minimally invasive diagnostics, making them more accessible to patients. Supportive regulatory frameworks and reimbursement schemes incentivize healthcare providers to incorporate liquid biopsies into routine clinical practice, accelerating adoption and market growth. Continued policy development is expected to further facilitate market expansion. • Strategic Collaborations and Investments: The market is witnessing increased collaborations between biotech firms, pharmaceutical companies, and research institutions to develop innovative liquid biopsy products. Investments in R&D are fueling technological advancements and expanding the test portfolio. These partnerships also facilitate clinical validation and regulatory approval processes, reducing time-to-market. Such strategic alliances enhance market credibility and foster innovation, ultimately broadening the application scope and accelerating growth in the liquid biopsy sector. The challenges in the liquid biopsy market are: • High Costs and Limited Reimbursement: Despite technological advancements, the high cost of liquid biopsy tests remains a significant barrier, especially in low- and middle-income countries. Limited reimbursement policies further restrict patient access and hinder widespread adoption. The lack of standardized pricing and coverage policies creates uncertainty for healthcare providers and payers, slowing market growth. Addressing cost issues and establishing comprehensive reimbursement frameworks are essential to ensure broader accessibility and to sustain market expansion. • Lack of Standardization and Validation: Variability in test performance, lack of standardized protocols, and limited clinical validation pose challenges to clinical adoption. Inconsistent results can undermine clinician confidence and delay regulatory approval processes. The absence of universally accepted guidelines hampers the integration of liquid biopsies into routine practice. Overcoming these issues requires extensive validation studies, consensus on testing procedures, and regulatory harmonization to ensure reliability and facilitate market growth. • Regulatory and Ethical Challenges: Navigating complex regulatory pathways and ensuring compliance with evolving standards is a significant hurdle. Additionally, ethical concerns related to genetic data privacy, informed consent, and potential misuse of information pose risks. Regulatory uncertainty can delay product approvals and market entry. Addressing these challenges necessitates clear regulatory frameworks, robust data protection measures, and stakeholder engagement to build trust and promote responsible innovation in the liquid biopsy domain. The liquid biopsy market is driven by technological innovations, rising cancer incidence, personalized medicine adoption, supportive policies, and strategic collaborations. However, high costs, lack of standardization, and regulatory complexities present notable challenges. These factors collectively influence the pace and scope of market growth. Overcoming barriers and leveraging drivers will be crucial for stakeholders aiming to expand access, improve diagnostic accuracy, and realize the full potential of liquid biopsies in clinical practice. The market's future depends on balancing innovation with regulatory and economic considerations to ensure sustainable growth and improved patient outcomes. List of Liquid Biopsy Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies liquid biopsy market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the liquid biopsy market companies profiled in this report include- • Bio-Rad Laboratories • QIAGEN • MDxHealth • Myriad Genetics • Biocept, Inc. • F. Hoffmann-La Roche Ltd. • Thermo Fisher Scientific Inc. • Illumina, Inc. • Cardiff Oncology • Guardant Health Liquid Biopsy Market by Segment The study includes a forecast for the global liquid biopsy market by product, circulating biomarker, application, end use, and region. Liquid Biopsy Market by Product [Value ($M) from 2019 to 2035]: • Assays Kits • Instruments • Services Liquid Biopsy Market by Circulating Biomarker [Value ($M) from 2019 to 2035]: • Circulating Tumor Cells • Circulating Tumor DNA • Cell-Free DNA • Extracellular Vesicles • Others Liquid Biopsy Market by Application [Value ($M) from 2019 to 2035]: • Oncology • Non-Cancer Liquid Biopsy Market by End Use [Value ($M) from 2019 to 2035]: • Reference Laboratories • Hospitals & Physician Laboratories • Academic & Research Centers • Others Liquid Biopsy Market by Region [Value ($M) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Liquid Biopsy Market The liquid biopsy market is growing rapidly for reasons including international expansion of the cancer diagnosis and treatment market, more effective technology, and the growing acceptance of liquid biopsies in the clinical market. As countries boost their healthcare and scientific research capacities, they are more actively seeking ways to better diagnose and treat disease, thus improving the health of their populations. Along with advances in healthcare technologies and greater acceptance of new diagnostic and treatments methods, the market for liquid biopsies is expected to continue its rapid growth. • United State: The United States has the largest liquid biopsy market share thanks to a competitive market, advanced research in new technologies, and recognition of the value of early and continuous cancer diagnosis and treatment. The focus of liquid biopsy research is personalized treatment. With a well-developed and funded scientific and medical research base, as well as continuous improvements in the regulatory environment for research and advanced medical diagnostics and treatments, the United States will retain its position as a primary market for liquid biopsies. • China: China’s large population and recent investments in research to improve cancer diagnostics have contributed to the rapid growth of China’s liquid biopsy market. Combinations of new diagnostic technologies with less invasive methods and increasing public awareness and demand for better diagnostics have also contributed to the market’s rapid growth in China. While China has a relatively large market for liquid biopsies, it still lags behind more developed nations. As China continues to strengthen its public healthcare and research sectors, it is likely to continue closing this gap. • Germany: Germany is focused on precision medicine and has a well-developed health care system. This has attracted numerous research institutions and biotech companies to Germany. Germany has improved its laws to make the approval process for new medical devices and diagnostic tests less bureaucratic. Germany funds numerous clinical trials to determine the safety and efficacy of new technologies. Once a technology has been clinically proven to be effective and safe, the German government encourages its implementation in the standard of care. Germany has established numerous partnerships and is active in research and development to further establish itself in the liquid biopsy market. • India: The market for liquid biopsy in India is rapidly developing. One of the largest barriers for cancer treatment has been the advanced stages at which the disease is often first detected. As the awareness for cancer and other diseases increases, so does the demand for diagnostics that help detect disease in its early stages. Numerous startups and established companies have developed and are developing rapid, affordable, and easy to use diagnostic tests to bring cancer and other disease screening to the general public. While there are numerous barriers to the wide spread adoption of new medical devices in India (including a lack of government reimbursement for many new diagnostic tests) the general public and private sector have worked to improve the Indian healthcare and biotech sectors. • Japan: Japan's market focuses on innovative and cutting edge medical devices and services. As the average age of the Japanese population increases, so does the demand for innovative medical diagnostics. Many of the larger companies operating in Japan are focused on developing next generation liquid biopsy tests. The Japanese government has programs in place to support innovative medical devices. These programs make Japan a desirable location for research and development in the medical field. Features of the Global Liquid Biopsy Market Market Size Estimates: liquid biopsy market size estimation in terms of value ($M). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: liquid biopsy market size by various segments, such as by product, circulating biomarker, application, end use, and region in terms of value ($M). Regional Analysis: liquid biopsy market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different product, circulating biomarker, application, end use, and regions for the liquid biopsy market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the liquid biopsy market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the liquid biopsy market by product (assays kits, instruments, and services), circulating biomarker (circulating tumor cells, circulating tumor DNA, cell-free DNA, extracellular vesicles, and others), application (oncology and non-cancer), end use (reference laboratories, hospitals & physician laboratories, academic & research centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?